Delayed reduction of hepatitis B viral load and dynamics of adefovir resistant variants during adefovir plus entecavir combination rescue therapy

Entecavir (ETV) added to adefovir (ADV) is recommended in the consensus for management of patients with ADV resistance. However, little attention has been focused on the delayed reduction of HBV DNA and dynamics of ADV-resistant variants during ADV–ETV combination rescue therapy in the clinical setting.